Plant Name: Bupleurum falcatum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GABBR1; | |
| FFAR4; FFAR1; | |
| GLA; FAAH; TDP1; BLM; CDA; TERT; HPGD; ALOX15; | |
| GABRR1; | |
| PPARA; PPARD; PPARG; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| KMT2A; | |
| ABCB1; | |
| SLC22A8; SLC22A6; SLC6A11; SLC6A1; SLC28A1; SLC28A3; | |
| LMNA; FABP5; FABP2; FABP4; FABP3; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C19; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 5.815E-08 | 7.729E-05 | ABCB1, BLM, FABP3, HPGD, NFKB1, PPARG, SLC22A6, SLC6A1, SLC6A11, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.250E-07 | 1.237E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.356E-06 | 7.171E-04 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.736E-06 | 8.399E-04 | ALOX15, FABP4, HIF1A, KMT2A, SLC6A1, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.230E-06 | 1.033E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.377E-06 | 1.388E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 5.216E-06 | 1.958E-03 | FFAR1, FFAR4, GABBR1, GABRR1, SLC22A6, SLC22A8, SLC28A1, SLC28A3, SLC6A1, SLC6A11, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 7.162E-06 | 2.497E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 7.224E-06 | 2.497E-03 | ABCB1, FFAR1, HIF1A, KMT2A, PPARD, PPARG, SLC6A1, TERT, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 7.847E-06 | 2.589E-03 | ABCB1, FABP4, FFAR4, HIF1A, LMNA, NFKB1, PPARA, PPARD, PPARG, TERT, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 8.935E-06 | 2.820E-03 | HIF1A, TERT, TP53 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.012E-05 | 2.978E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.012E-05 | 2.978E-03 | SLC28A1, SLC28A3 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.248E-05 | 3.575E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.329E-05 | 3.759E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.453E-05 | 4.055E-03 | FABP3, FFAR1, PPARG, TLR2 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 2.022E-05 | 5.379E-03 | SLC6A1, SLC6A11 |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 2.419E-05 | 6.055E-03 | BLM, PPARG, SLC6A1, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 3.365E-05 | 7.900E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 4.422E-05 | 9.928E-03 | PPARA, TERT, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.281E-11 | 3.642E-09 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 1.851E-05 | 6.848E-04 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.679E-05 | 6.848E-04 | HPGD; KMT2A; PPARG; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.366E-04 | 1.211E-02 | GABBR1; PPARA; NFKB1; TSHR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.825E-04 | 1.263E-02 | PPARG; HIF1A; TP53; NFKB1; PPARD |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.415E-04 | 1.263E-02 | PPARG; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.024E-03 | 2.042E-02 | LMNA; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.748E-03 | 2.042E-02 | PPARA; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.863E-03 | 2.042E-02 | TP53; NFKB1; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.281E-03 | 2.110E-02 | TP53; NFKB1; TLR2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.240E-03 | 1.721E-02 | PPARG; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.240E-03 | 1.721E-02 | ALOX15; CYP2C19 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.749E-03 | 3.392E-02 | TP53; HIF1A; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 4.442E-03 | 3.278E-02 | TP53; NFKB1; TLR2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 4.406E-03 | 3.278E-02 | NFKB1; TLR2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.724E-03 | 3.278E-02 | NFKB1; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.564E-03 | 3.278E-02 | FABP4; TSHR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.566E-03 | 3.392E-02 | ALOX15; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.286E-03 | 3.392E-02 | TP53; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 6.102E-03 | 3.392E-02 | NFKB1; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.472E-03 | 3.392E-02 | TP53; HIF1A |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.107E-02 | 4.433E-02 | TERT; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.640E-03 | 3.392E-02 | TP53; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 7.045E-03 | 3.392E-02 | PPARA; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.640E-03 | 3.392E-02 | NFKB1; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.118E-02 | 4.433E-02 | TP53; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.340E-02 | 4.910E-02 | GABBR1; GABRR1; TSHR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.241E-03 | 3.392E-02 | ABCB1; SLC22A8 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.047E-02 | 4.433E-02 | TP53; NFKB1 |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.167E-02 | 4.466E-02 | GABBR1; GABRR1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.423E-02 | 4.910E-02 | FAAH; GABRR1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.396E-02 | 4.910E-02 | NFKB1; TLR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.612E-02 | 4.930E-02 | ABCB1; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.477E-02 | 4.910E-02 | HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.559E-02 | 4.930E-02 | NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.504E-02 | 4.910E-02 | NFKB1; TLR2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.643E-02 | 4.930E-02 | PPARA; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; CDA; TP53; TLR2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; HIF1A; TP53; NFKB1; TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARD; FFAR1; PPARG; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; TERT |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |